Executive Vice President
On November 11, 2015, a Philadelphia jury returned a $1.75 million verdict in favor of 21-year-old Nicholas Murray who claimed that Janssen Pharmaceutical’s antipsychotic drug Risperdal caused him to develop male breasts.
Murray was first prescribed Risperdal in 2003, three years before the FDA approved the drug for use in children, and continued to take the drug until 2008. Murray claimed to never have been warned by doctors of the risks of the drug including the risk of developing gynecomastia, a medical condition that causes boys to grow excessive breast tissue. Murray’s case is the third to receive a plaintiff-positive result out of the nearly 1,500 pending Risperdal cases in Pennsylvania.
The case is: Murray v. Janssen Pharmaceuticals Inc., No. 130401990, Court of Common Pleas, Philadelphia County (Philadelphia).
Plaintiff Support offers a variety of settlement funding services to help plaintiffs and attorneys during and after a personal injury case. Learn more about how we can help you.